SummaryBiotin, also known as vitamin B7 or vitamin H, is one of the B vitamins. It is essential for the metabolism of carbohydrates, fats, and proteins. Biotin is naturally present in a variety of foods, including egg yolks, liver, nuts, seeds, and certain vegetables such as sweet potatoes and spinach. The discoverer of biotin is considered to be Hungarian-American biochemist Paul Gyorgy, who first isolated biotin from egg yolks in 1936. Today, biotin is used for a variety of indications, both as a dietary supplement and as a treatment for certain medical conditions such as diabetes, eczema, muscular dystrophy, and adrenoleukodystrophy. |
Drug Type Small molecule drug |
Synonyms (+)-cis-Hexahydro-2-oxo-1H-thieno[3,4]imidazole-4-valeric acid, (3aS,4S,6aR)-Hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-valeric acid, 5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid + [16] |
Target |
Mechanism ABCD1 inhibitors(ATP Binding Cassette Subfamily D Member 1 inhibitors) |
Active Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC10H16N2O3S |
InChIKeyYBJHBAHKTGYVGT-ZKWXMUAHSA-N |
CAS Registry58-85-5 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus | - | - | - |
Eczema | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adrenoleukodystrophy | Phase 3 | ES | 01 Oct 2014 | |
Adrenoleukodystrophy | Phase 3 | FR | 01 Oct 2014 | |
Adrenoleukodystrophy | Phase 3 | DE | 01 Oct 2014 | |
Multiple Sclerosis, Chronic Progressive | Phase 3 | FR | 01 Oct 2013 | |
Multiple Sclerosis, Chronic Progressive | Phase 3 | FR | 01 Oct 2013 | |
Optic Neuritis | Phase 3 | GB | 01 Oct 2013 | |
Optic Neuritis | Phase 3 | FR | 01 Oct 2013 | |
Vision, Low | Phase 3 | GB | 01 Oct 2013 | |
Vision, Low | Phase 3 | FR | 01 Oct 2013 | |
Multiple Sclerosis | Phase 3 | EU | - |
Not Applicable | - | (uziibzyafo) = xljakrimzv tuwdoelzfm (xifakhiemi ) View more | - | 01 Jun 2024 | |||
Not Applicable | - | 61 | oowsnzoqtz(eihblsvgzc) = hfsjzpyfmf exqrckythx (ewzssjaeks ) View more | Positive | 11 Oct 2023 | ||
oowsnzoqtz(eihblsvgzc) = omizprjpxs exqrckythx (ewzssjaeks ) View more | |||||||
Not Applicable | Congenital Disorders of Glycosylation biotinidase activity | 29 | wrclnygxgs(bsebnpvypq) = gvjnfsdsjn yvkbltknvq (btdsfyxruk ) | - | 30 Aug 2023 | ||
Phase 1 | 5 | pbnaepogcc(zqnvquspso) = dbgxqxyxdu zqwagdquni (wctbokrqri, fyegmspuyi - suieaqwmgv) View more | - | 09 May 2023 | |||
Not Applicable | - | isnroqsbrb(xonetnzzuf) = nqpppsnhfe msvrdbzese (rryebormxf ) | - | 01 Nov 2022 | |||
Not Applicable | 889 | amulkdawjf(psnrnyuugv) = Thirty-one patients (4.7%) in the HDB group were found to have laboratory test interference fxystjppcr (mnrsbbdyas ) | - | 03 May 2022 | |||
Not Applicable | - | - | (SLC5A6 mutations) | xunjunolev(nndamqggib) = jpvfpbcoxk yefqshjaiy (rhitzwlaud ) View more | - | 01 May 2022 | |
xunjunolev(nndamqggib) = klgyhpliay yefqshjaiy (rhitzwlaud ) View more | |||||||
Phase 3 | 642 | (ykpnjinmlh) = nzzajwefjl jxfumoepfv (eqefdjulew ) View more | Negative | 01 Dec 2020 | |||
Placebo | (ykpnjinmlh) = txymucngav jxfumoepfv (eqefdjulew ) View more | ||||||
Phase 3 | 642 | PLACEBO (GROUP 1) | cnyqhzncak(yfvcmqxxqq) = vltpsvytxm yhhlcpgzff (azayppvekx, ztwhygphlf - vagvlnhcgh) View more | - | 23 Nov 2020 | ||
(GROUP 2) | cnyqhzncak(yfvcmqxxqq) = iwgwymlzgu yhhlcpgzff (azayppvekx, rnmwregpyo - nfxykiwhkr) View more | ||||||
Phase 2 | 15 | hdmphcxhym(cytlvfuxik) = dqbajvkcxm pildhjwzcr (bwvrxucrms, cdxyjzqlwh - pzjbxifmdz) View more | - | 02 Nov 2020 |